These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7510030)

  • 1. Chagas' disease: carcinogenic activity of the antitrypanosomal nitroarenes in mice.
    Teixeira AR; Calixto MA; Teixeira ML
    Mutat Res; 1994 Mar; 305(2):189-96. PubMed ID: 7510030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant, non-Hodgkin's lymphomas in Trypanosoma cruzi-infected rabbits treated with nitroarenes.
    Teixeira AR; Silva R; Cunha Neto E; Santana JM; Rizzo LV
    J Comp Pathol; 1990 Jul; 103(1):37-48. PubMed ID: 2203830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
    Cabrera E; Murguiondo MG; Arias MG; Arredondo C; Pintos C; Aguirre G; Fernández M; Basmadjián Y; Rosa R; Pacheco JP; Raymondo S; Di Maio R; González M; Cerecetto H
    Eur J Med Chem; 2009 Oct; 44(10):3909-14. PubMed ID: 19446929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives.
    Braga MS; Lauria-Pires L; Argañaraz ER; Nascimento RJ; Teixeira AR
    Rev Inst Med Trop Sao Paulo; 2000; 42(3):157-61. PubMed ID: 10887376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole.
    Teixeira AR; Córdoba JC; Souto Maior I; Solórzano E
    Am J Trop Med Hyg; 1990 Aug; 43(2):146-58. PubMed ID: 2117856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitrypanosomal therapy for chronic Chagas' disease.
    Bern C
    N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

  • 8. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis).
    Castro JA; de Mecca MM; Bartel LC
    Hum Exp Toxicol; 2006 Aug; 25(8):471-9. PubMed ID: 16937919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trypanocidal nitroarene treatment of experimental Trypanosoma cruzi infection does not prevent progression of chronic-phase heart lesions in rabbits.
    Teixeira AR; Cunha Neto E; Rizzo LV; Silva R
    J Infect Dis; 1990 Dec; 162(6):1420. PubMed ID: 2121842
    [No Abstract]   [Full Text] [Related]  

  • 10. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 11. Etiological treatment for infection by Trypanosoma cruzi.
    Amato Neto V
    Mem Inst Oswaldo Cruz; 1999; 94 Suppl 1():337-9. PubMed ID: 10677751
    [No Abstract]   [Full Text] [Related]  

  • 12. Antitrypanosomal therapy for chronic Chagas' disease.
    Bestetti RB; Cardinalli-Neto A
    N Engl J Med; 2011 Sep; 365(13):1258-9; author reply 1259. PubMed ID: 21991909
    [No Abstract]   [Full Text] [Related]  

  • 13. Antitrypanosomal therapy for chronic Chagas' disease.
    Garcia-Bournissen F; Altcheh J
    N Engl J Med; 2011 Sep; 365(13):1258; author reply 1259. PubMed ID: 21991908
    [No Abstract]   [Full Text] [Related]  

  • 14. Chronic Chagas' disease in the mouse. IV. Effect of trypanocidal drugs.
    Laguens RP; Cabeza Meckert P; Chambó JG; Gelpi R
    Medicina (B Aires); 1983; 43(2):126-30. PubMed ID: 6420640
    [No Abstract]   [Full Text] [Related]  

  • 15. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
    Filardi LS; Brener Z
    Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of complement mediated lysis technic in patients with chronic Chagas' disease treated with trypanocidal drugs].
    Levy AM; Pereira VL; Boainain E
    Rev Inst Med Trop Sao Paulo; 1988; 30(1):32-9. PubMed ID: 3146793
    [No Abstract]   [Full Text] [Related]  

  • 17. Current drug therapy and pharmaceutical challenges for Chagas disease.
    Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
    Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina.
    Sosa Estani S; Segura EL
    Mem Inst Oswaldo Cruz; 1999; 94 Suppl 1():363-5. PubMed ID: 10677756
    [No Abstract]   [Full Text] [Related]  

  • 19. The efficacy of a novel compound, (e)-1-(4'-bromo-4-biphenylyl)-1-(4-chlorophenyl)-3-dimethylaminoprop-1-ene against Trypanosoma cruzi in mice.
    Barrett PA; Beveridge E; Bull D; Caldwell IC; Islip PJ; Neal RA; Woods NC
    Experientia; 1982 Mar; 38(3):338-9. PubMed ID: 6804255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiparasitic nitroimidazoles. 8. Derivatives of 2-(4-formylstyryl)-5-nitro-1-vinylimidazole.
    Ross WJ; Jamieson WB
    J Med Chem; 1975 Feb; 18(2):158-61. PubMed ID: 804551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.